Cargando…

The treatment of melasma by silymarin cream

BACKGROUND: Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of...

Descripción completa

Detalles Bibliográficos
Autor principal: Altaei, Tagreed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519762/
https://www.ncbi.nlm.nih.gov/pubmed/23031632
http://dx.doi.org/10.1186/1471-5945-12-18
_version_ 1782252731521564672
author Altaei, Tagreed
author_facet Altaei, Tagreed
author_sort Altaei, Tagreed
collection PubMed
description BACKGROUND: Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of this study were the assessment of safety and efficacy of topical Silymain (SM) cream in a double-blind placebo controlled study for treatment of melasma patients. METHODS: Experimentally on 24 Albino rabbits were randomly divided into 4 equal groups. [A] No treatment, [B] received placebo, [C] treated with SM cream (0.1), & [D] treated by SM (0.2), were applied topically before UV sun light exposure for 30 days, assessed clinically & tissue pathology. Clinically on 96 adults diagnosed with melasma randomized to three equal groups to receive one of the tested drugs applied twice daily for 4 weeks, evaluated by the response; lesion size, melasma area and severity index score, Physician global assessment, and subjective assessment. RESULTS: The Clinical and histopathology observations were reduced significantly in SM groups. Clinically; all patients showed significant excellent pigment improvement & lesion size reduction with SM treatments from the 1(st) week. All patients were fully satisfied 100%. No side effects were observed. CONCLUSIONS: Silymarin showed tremendous improvement of melasma in a dose-dependent manner, and was effective in prevention of skin damage caused by U.V. sunlight. It is a safe new candidate effective treatment for melasma. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry - ACTRN12612000602820
format Online
Article
Text
id pubmed-3519762
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35197622012-12-12 The treatment of melasma by silymarin cream Altaei, Tagreed BMC Dermatol Research Article BACKGROUND: Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of this study were the assessment of safety and efficacy of topical Silymain (SM) cream in a double-blind placebo controlled study for treatment of melasma patients. METHODS: Experimentally on 24 Albino rabbits were randomly divided into 4 equal groups. [A] No treatment, [B] received placebo, [C] treated with SM cream (0.1), & [D] treated by SM (0.2), were applied topically before UV sun light exposure for 30 days, assessed clinically & tissue pathology. Clinically on 96 adults diagnosed with melasma randomized to three equal groups to receive one of the tested drugs applied twice daily for 4 weeks, evaluated by the response; lesion size, melasma area and severity index score, Physician global assessment, and subjective assessment. RESULTS: The Clinical and histopathology observations were reduced significantly in SM groups. Clinically; all patients showed significant excellent pigment improvement & lesion size reduction with SM treatments from the 1(st) week. All patients were fully satisfied 100%. No side effects were observed. CONCLUSIONS: Silymarin showed tremendous improvement of melasma in a dose-dependent manner, and was effective in prevention of skin damage caused by U.V. sunlight. It is a safe new candidate effective treatment for melasma. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry - ACTRN12612000602820 BioMed Central 2012-10-02 /pmc/articles/PMC3519762/ /pubmed/23031632 http://dx.doi.org/10.1186/1471-5945-12-18 Text en Copyright ©2012 Altaei; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Altaei, Tagreed
The treatment of melasma by silymarin cream
title The treatment of melasma by silymarin cream
title_full The treatment of melasma by silymarin cream
title_fullStr The treatment of melasma by silymarin cream
title_full_unstemmed The treatment of melasma by silymarin cream
title_short The treatment of melasma by silymarin cream
title_sort treatment of melasma by silymarin cream
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519762/
https://www.ncbi.nlm.nih.gov/pubmed/23031632
http://dx.doi.org/10.1186/1471-5945-12-18
work_keys_str_mv AT altaeitagreed thetreatmentofmelasmabysilymarincream
AT altaeitagreed treatmentofmelasmabysilymarincream